Agenda

Biomarkers in HER2+ Breast Cancer: Guiding Therapy or Still a Work in Progress?

Paolo Tarantino, MD

‍

HER2 Testing in the Era of Novel ADC: Refining Its Role in Precision Oncology

David Rimm, MD, PhD

‍

HER2+ Breast Cancer Brain Metastases: Navigating Challenges and Innovations in Care

Sarah L. Sammons, MD

‍

Audience Q&A and Panel Discussion

David Rimm, MD, PhD; Sarah L. Sammons, MD; Paolo Tarantino, MD